Periungual Pyogenic Granuloma-Like Lesions During Isotretinoin Treatment for Acne: Two Case Reports and a Literature Review

1. Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol 1983;119:808-11.10.1001/archderm.1983.01650340018012Search in Google Scholar

2. Campbell JP, Grekin RC, Ellis CN, Matsuda-John SS, Swanson NA, Voorhees JJ. Retinoid therapy is associated with excess granulation tissue responses. J Am Acad Dermatol 1983;9:708-13.10.1016/S0190-9622(83)70184-2Search in Google Scholar

3. Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol 1988;18:543-52.10.1016/S0190-9622(88)70078-XSearch in Google Scholar

4. Piraccini BM, Bellavista S, Misciali C, Tosti A, de Berker D, Richert B. Periungual and subungual pyogenic granuloma. Br J Dermatol 2010;163:941-53.10.1111/j.1365-2133.2010.09906.xSearch in Google Scholar

5. Armstrong K, Weinstein M. Pyogenic granulomas during isotretinoin therapy. J Dermatol Case Rep 2011;5:5-7.10.3315/jdcr.2011.1062Search in Google Scholar

6. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984;10:677-8.10.1016/S0190-9622(84)80289-3Search in Google Scholar

7. MacKenzie-Wood AR, Wood G. Pyogenic granuloma-like lesions in a patient using topical tretinoin. Australas J Dermatol 1998;39:248-50.10.1111/j.1440-0960.1998.tb01483.x9838723Search in Google Scholar

8. Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010;51:248-53.10.1111/j.1440-0960.2010.00657.x21198520Search in Google Scholar

9. Gutzmer R, Wollenberg A, Ugurel S, Homey B, Ganser A, Kapp A. Cutaneous side effects of new antitumor drugs. Clinical features and management. Dtsch Arztebl Int 2012;109(8):133–40.Search in Google Scholar

10. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72:203-18.10.1016/j.jaad.2014.07.03225592338Search in Google Scholar

11. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221-36.10.1016/j.jaad.2014.07.03325592339Search in Google Scholar

12. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:4646-8.10.1200/JCO.2004.02.16815542815Search in Google Scholar

13. Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058–64.10.1158/1078-0432.CCR-09-176620103661Search in Google Scholar

14. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009;1:177-87.10.4161/derm.1.3.8258283591120436886Search in Google Scholar

15. Guruvayoorappan C, Kuttan G. 13 cis-retinoic acid regulates cytokine production and inhibits angiogenesis by disrupting endothelial cell migration and tube formation. J Exp Ther Oncol 2008;7:173-82.Search in Google Scholar

16. Hasegawa K, Namekawa SH, Saga Y. MEK/ERK signaling directly and indirectly contributes to the cyclical self-renewal of spermatogonial stem cells. Stem Cells 2013;31:2517-27.10.1002/stem.1486383420023897718Search in Google Scholar